Historien om alt
374 - Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
00:00
00:00
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.
For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Episoder
374-
Ep. 364 - UCB’s Candid buy, Grand Rounds and leukodystrophies
Lyttet
373-
Ep. 363 - New targets at AACR, biopharma deals, Kurma fund
Lyttet
372-
Ep. 362 - AACR: Data and de-risking
Lyttet
371-
Ep. 361 - Kelonia, Kailera, pyschedelics and T cell engagers
Lyttet
370-
